Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute (HCI), shared a post on X:
Abstract 16
ASCO GU 2026 by Maha Hussain BRCAAway Ph2 trial in 1L mCRPC w/ BRCA1/2 or ATM alterations prostate cancer improved OS (68 mo) w/ abi + olaparib vs each monotherapy or sequential use supports upfront PARPi+ARPI.
Title: Overall survival from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCAAway)
Authors: Maha H. Hussain, Masha Kocherginsky, Channing J. Paller, Neeraj Agarwal, Latifa A. Bazzi, Nabil Adra, Zachery R. Reichert, Jingsong Zhang, Joel Picus, Russell Z. Szmulewitz, Scott T. Tagawa, Timothy M. Kuzel, Young E. Whang, Ryan D. Stephenson, Robert Dreicer, Daniel Shevrin, Matthew Rettig, Emmanuel S. Antonarakis
Read The Full Article
Abstract 305
ASCO GU 2026 by Amar Kishan POSEIDON IPD meta-analysis of post-op RT ± ADT in recurrent prostate cancer No OS benefit from adding ADT to RT (HR 0.87, p=0.06) at PSA <0.5 ng/mL.
Title: Hormone therapy use and duration with post-operative radiotherapy for recurrent prostate cancer: An individual patient data meta-analysis
Authors: Amar U. Kishan, Yilun Sun, Chris Parker, Matthew R. Sydes, Paul H. Sargos, Sylvie Chabaud, Meryem Brihoum, Pascal Pommier, Luca F. Valle, Soumyajit Roy, Michael L. Steinberg, Angela Y. Jia, Jason A. Efstathiou, James J. Dignam, Alan Pollack, Howard M. Sandler, Paul Nguyen, Daniel E. Spratt
Read The Full Article
Abstract 19
ASCO GU 2026 by Fred Saad. Ph1 trial of 225Ac-PSMA-Trillium in mCRPC prostate cancer No DLTs promising PSA50 83% at 125 kBq/kg (RDE), ORR 46%, response in PSMA PET SUVmean>10.
Title: First-in-human assessment of actinium-225-prostate-specific membrane antigen (225Ac-PSMA)-Trillium (BAY 3563254) in mCRPC: Dose-escalation results of the phase 1 PAnTHa study
Authors: Fred Saad, Sebastien J. Hotte, Anuradha Jayaram, Carlos Artigas, Ramy Saleh, Corinne Maurice-Dror, Siska Van Bruwaene, Cristina Boixareu, Nina Tunariu, Zineb Hamilou, Daniel Juneau, Charles Glaus, Katrina Walker, Ying (Amanda) Wang, Christoph M. Griessinger, Abdel Nasser Hosein, Johann S. De Bono
Read The Full Article
Abstract 633
ASCO GU 2026 by Tom Powles. IMvigor011 ctDNA dynamics in MIBC bladder cancer early ctDNA + linked to worse DFS Atezo ctDNA vs placebo (P=0.009) ctDNA clearance associated with improved DFS and OS.
Title: Circulating tumor (ct)DNA-guided adjuvant atezolizumab (atezo) in muscle-invasive bladder cancer (MIBC): Exploratory analysis of ctDNA dynamics in the IMvigor011 trial.
Authors: Thomas Powles, Jessia Grindheim, Mesut Yilmaz, Grigorios Rallis, Mahmut Gumus, Consuelo Buttigliero, Teresa Bonfill, Franco Nole, Ho Kyung Seo, Michaela Matouskova, Iwona Skoneczna, Wim Demey, Patrizia Giannatempo, Sylvie Rottey, Damien Pouessel, Syed A. Hussain, Elizabeth E. Steinberg, Richard Price, Yohann Loriot, Joaquim Bellmunt
Read The Full Article
Abstract 635
ASCO GU 2026 by Andrea Necchi. SunRISe-2 in MIBC bladder cancer pts ineligible/declining surgery Gem-iDRS+CET did not improve bladder-intact EFS vs chemoRT (HR 1.71) MFS/OS similar great efforts.
Title: Gemcitabine intravesical system (Gem-iDRS) in combination with cetrelimab (CET) versus chemoradiotherapy (CRT) in muscle-invasive bladder cancer (MIBC): SunRISe-2 final results
Authors: Andrea Necchi, Stephen B. Williams, Phouc Tran, Yohann Loriot, Mariaconsiglia Ferriero, Hernan J. Cutuli, Makito Miyake, Guenter Niegisch, Paul Nguyen, Siamak Daneshmand, Felipe Villacampa-Aubá, Wolfgang Jessner, Meggan Tammaro, Marietta Kashmer, Jenna Carcione, Monelle Tamegnon, Hussein Sweiti, Robert A. Somer, Sumeet K. Bhanvadia, Shahrokh F. Shariat
Read The Full Aricle
Abstract 636
ASCO GU 2026 by Michiel van der Heijden. NIAGARA trial bladder cancer Periop durvalumab+NAC urine utDNA clearance (39% vs 27%) utDNA clearance pCR (72% vs 18%), dual utDNA/ctDNA- showed 90% 24-mo EFS.
Title: Urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA
Authors: Michiel S. Van Der Heijden, Matthew D. Galsky, Ricky Joshi, James W. Catto, Joshua J. Meeks, Hiroyuki Nishiyama, Hikmat Al-Ahmadie, Lorenzo Antonuzzo, Toan Vu Quang, Yousef Zakharia, Vagif Atduev, Bernhard J. Eigl, Cristina Suárez, Svetlana Ho, Huiling Xiong, Agrin Moeini Mortazavi, Yashaswi Shrestha, Thomas Powles
Read The Full Article
Abstract 638
ASCO GU 2026 by Anders Ullen. KEYNOTE-905 in cisplatin ineligible MIBC bladder cancer Periop EV+pembro + RC/PLND OS, pCR, pDS, surgical outcomes and DFS vs surgery alone Supports EV+pembro as new SOC.
Title: Pathological outcomes and disease-free survival (DFS) in KEYNOTE-905: Neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible
Authors: Anders Ullén, Christof Vulsteke, Jens Bedke, Steffen Rausch, Shilpa Gupta, Seok-Ho Kang, Jeanny B. Aragon-Ching, Laura Bernal Vaca, Viktor Paramonov, Avivit Peer, Viktor Stus, Vagif Atduev, Keita Nakane, Jasmine Lichfield, Changting Meng, David Huang, Chethan Ramamurthy, Blanca Homet Moreno, Matthew D. Galsky
Read The Full Article
Abstract 587
ASCO GU 2026 by Jennifer King. Ph2 cabozantinib in relapsed/refractory germ cell tumors (n=44) Clinical benefit in >40% pts Cabo is the 1st non-cytotoxic agent w/ meaningful activity in this setting.
Title: A phase II trial of cabozantinib in relapsed refractory germ-cell tumors (GCT)
Authors: Jennifer King, Sandra K. Althouse, Yong Zang, Tareq Salous, Nasser H. Hanna, Lawrence H. Einhorn, Nabil Adra
Read The Full Article
Abstract 537
ASCO GU 2026 by Chad Tang. Oligomet RCC kidney cancer treated w/ MDT KIM-1 and ctDNA independently predicted recurrence and survival Combined w/ clinical factors (K-COMPASS) risk stratification.
Title: Circulating KIM-1 and ctDNA as prognostic markers in oligometastatic clear cell renal cell carcinoma (ccRCC): The K-COMPASS model
Authors: Chad Tang, Aaron Seo, Alexander D. Sherry, Peng Yang, Kieko Hara, Kanishka Sircar, Giannicola Genovese, Eric Jonasch, Amishi Y. Shah, Sarah Ratzel, Ashley Acevedo, Christopher J. Battey, Clara Steiner, Liliana Ascione, Xiaowen Liu, Nizar M. Tannir, Toni K. Choueiri, Pavlos Msaouel, Wenxin Xu
Read The Full Article
Abstract 676
ASCO GU 2026 by Georges Gebrael. In real-world US advanced bladder cancer pts Platinum-based and targeted Rx are most common 2L Post-EV+Pembro outcomes are modest.
Title: Treatment patterns and outcomes with second line (2L) therapies in patients (pts) with advanced urothelial carcinoma (aUC) previously treated with first line (1L) enfortumab vedotin (EV) with pembrolizumab (pembro)
Authors: Georges Gebrael, Yeonjung Jo, Zeynep Irem Ozay, Edwin Lin, Nicolas Sayegh, Micah Ostrowski, Varun Nandakumar, Chadi Hage Chehade, Richard Ji, Ethan Murdock, Patrick Campbell, Vinay Mathew Thomas, Sumati Gupta, Benjamin L. Maughan, Umang Swami, Neeraj Agarwal
Read The Full Article
Abstract 219
ASCO GU 2026 by Georges Gebrael. Distinct genomic landscape of BRCA1/2 wild type HRDsig+ prostate cancer (n=23,336 pts Foundation Medicine) compared to HRDsig– prostate cancer may impact development of combination Rx.
Title: Homologous recombination deficiency signature (HRDsig) status in BRCA1/2 wild type (BRCA1/2wt) clinically advanced prostate cancer (CAPC)
Authors: Georges Gebrael, Dean C. Pavlick, Ole Gjoerup, Petros Grivas, Sumanta K. Pal, Shilpa Gupta, Roger Li, Ashish M. Kamat, Joseph M. Jacob, Alina Basnet, Liang Cheng, Douglas I. Lin, Hanan Goldberg, Andrea Necchi, Gennady Bratslavsky, Philippe E. Spiess, Ryon P. Graf, Jeffrey S. Ross, Neeraj Agarwal
Read The Full Article
Abstract 101
ASCO GU 2026 by Micah Ostrowski. Real-world study of 850 pts w/ Lu-177 treated mCRPC prostate cancer in Flatiron Health. Lu-177 remained effective regardless of prior taxane exposure.
Title: Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium Lu 177 vipivotide tetraxetan (Lu) by prior taxane exposure
Authors: Micah Ostrowski, Yeonjung Jo, Georges Gebrael, Zeynep Irem Ozay, Varun Nandakumar, Edwin Lin, Nicolas Sayegh, Ayana Srivastava, Vinay Mathew Thomas, Haoran Li, Benjamin L. Maughan, Neeraj Agarwal, Umang Swami
Read The Full Article
Abstract 103
ASCO GU 2026 by Martin Schoen. Real-world cohort of elderly/frail veterans w/ de novo mHSPC receiving ADT +/- ARPIs prostate cancer ARPI + ADT improved OS regardless of old age or frailty.
Title: Overall survival (OS) in elderly, frail, or high comorbidity veterans receiving androgen receptor pathway inhibitors (ARPIs) with androgen-deprivation therapy (ADT) vs ADT alone for de novo metastatic castration-sensitive prostate cancer (mCSPC)
Authors: Martin W. Schoen, Jason M. Doherty, Nader N. El-Chaar, Jasmina I. Ivanova, Brian Talon, Daniel B. Eaton Jr., Di Zhao, Jason Cohen, Maelys Touya
Read The Full Article
Abstract 92
ASCO GU 2026 by Varun Nandakumar. End-of-life (EOL) Rx analysis of ~10,000 pts w/ mCRPC prostate cancer in Flatiron Health ~60% remained on Rx in last 3 mo of life need for more patient-centered EOL care.
Title: End-of-life treatment patterns in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors: Varun Nandakumar, Yeonjung Jo, Georges Gebrael, Zeynep Irem Ozay, Nicolas Sayegh, Chadi Hage Chehade, Micah Ostrowski, Edwin Lin, Ethan Murdock, Benjamin L. Maughan, Neeraj Agarwal, Umang Swami
Read The Full Article
Other articles about ASCO on OncoDaily.
